Table 4.
Histopathological changes in dystrophic muscles pre- and at the end of 6-month prednisone therapy. The micrometer (µm) represents measurement unit of muscle fibre size
| DMD Range (Mean ± SD) | BMD Range (Mean ± SD) | LGMD Range (Mean ± SD) | ||||
|---|---|---|---|---|---|---|
| Histopathological changes | Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | Pre-treatment | Post-treatment |
| Fibre size variation | 2.4 ± 0.5 | 1.7 ± 0.7** | 2.3 ± 0.5 | 1.3 ± 0.8* | 2.0 ± 0.6 | 2.3 ± 0.5 |
| Internalization of nucle | 2.1 ± 0.8 | 1.1 ± 1.1* | 1.5 ± 0.8 | 0.8 ± 0.7 | 0.8 ± 1.0 | 1.0 ± 0.8 |
| Degeneration and necrosis | 2.5 ± 0.8 | 1.4 ± 1.3** | 2.2 ± 0.7 | 0.6 ± 0.4** | 2.2 ± 0.4 | 2.0 ± 0.6 |
| Regeneration | 0.6 ± 0.9 | 1.9 ± 0.6*** | 0.5 ± 0.8 | 2.2 ± 0.4** | 1.0 ± 1.0 | 0.8 ± 1.0 |
| Endomysial connective tissue proliferation | 2.1 ± 0.8 | 1.1 ± 1.1** | 2.2 ± 0.7 | 0.8 ± 0.8* | 1.7 ± 1.2 | 2.2 ± 1.5 |
BMD, Becker muscular dystrophies; DMD, Duchenne muscular dystrophies; LGMD, limb girdle muscular dystrophies.
*
P < 0.05
**
P < 0.01
***
P < 0.001.